Today, Jingtai Technology, driven by AI+robots, is developing new drugs and materials（2228.HK）Announced that its AI innovation research and development platform has successfully developed two innovative topical efficacy ingredients for hair growth and fixation needs——Small molecule Remeanation ™(XTP-118) andPeptide AquaKine ™(XTP-016)， The combination formula of these "twin star" molecules has been validated for multidimensional efficacy,It has demonstrated unique advantages in terms of effectiveness, safety, and speed of onset.Both molecules have successfully obtained registration in the International Catalogue of Cosmetic Ingredient Standard Names (INCI), and their combination formula has been incubated by Jingtai Technology for consumer brand Groland to complete facility registration and product listing for cosmetic products at the US Food and Drug Administration (FDA), and will soon be launched in overseas markets; Meanwhile, the relevant ingredients are accelerating the completion of domestic raw material filing work.

Currently, hair loss has become a global challenge. According to statistics, the number of people affected by hair loss worldwide has exceeded 2.5 billion and continues to increase. Among them, the number of people suffering from hair loss in China has reached 250 million, and the trend of youthfulness is significant - a survey shows that by 2024, the total proportion of hair loss in China's post-80s and post-90s generations will exceed 70%. Faced with the long-standing biomedical challenge of hair loss, the consumer market has long lacked truly safe, efficient, effective, and universally applicable solutions. Existing products often suffer from multiple pain points due to unclear mechanisms of action, including low user response rates, increased risk of early hair loss, and hormonal imbalances caused by poor metabolism in the body.

Faced with the above challenges, MIT based Jingtai Technology relies on its leading AI+robot molecular research and development capabilities to directly target the core biological targets of abnormal hair loss, and deeply explore the key biomarkers for the entire hair growth cycle, developing the small molecule Remeanagen ™、 Peptide AquaKine ™ Two innovative maintenance ingredients, combined into a synergistic formula, bring a comprehensive upgrade of scalp maintenance and hair loss prevention effects, which is expected to bring efficient and safe new choices to the vast global population of hair loss, demonstrating huge market potential.

Cracking the three core challenges of hair volume maintenance:

The Innovation Path of Jingtai AI

The core challenge of hair regeneration lies in the complexity of molecular design, which requires efficient penetration of the skin barrier, precise activation of dormant hair follicles, and continuous nutritional optimization of the hair growth microenvironment. The core advantage of Jingtai Technology's AI platform lies in its ability to perform precise molecular design and efficient iterative optimization for complex targets. Based on this platform capability, Jingtai Technology has achieved breakthrough innovation and solved the triple key challenges of maintaining hair growth:

●1. "Transparent": Overcoming barriers and achieving efficient delivery

The first challenge for topical efficacy products is penetrating the scalp's stratum corneum. If the transdermal absorption ability is poor, all the benefits cannot be discussed. Jingtai Technology's AI platform has participated in challenging drug development projects such as designing high penetration peptides for eczema drugs, accumulating rich experience and methodology to optimize the permeability of molecules in a targeted manner, enabling Remeanation ™ And AquaKine ™ It has a skin absorption efficiency far exceeding that of ordinary ingredients, laying a solid foundation for the full utilization of subsequent effects.

●2. "Stimulate": awaken dormant seeds, maintain and prevent them from falling off at the source

Remeanagen ™ The birth of XTP-118 is a paradigm achievement in AI exploration of unknown chemical spaces. Jingtai Technology utilizes its information mining platform Patsight ™ Lock in key biological targets and use AI screening to design innovative small molecule structures that are difficult for human chemists to imagine, unlocking key biological functions.

Remeanagen ™ The core mechanism of action is to effectively activate dormant hair follicle stem cells, promote their re-entry into the growth phase, and significantly prolong this cycle¹The fluorescence comparison experiment and user cases clearly demonstrate its ability to activate and improve the healthy growth status of the scalp, achieving filling and preventing detachment at the source²During the testing period, multiple middle-aged and elderly participants who had been bald for years developed new hair in a short period of time³.

●3. "Nourishing": nourishing the fertile soil for growth, consolidating abundant and beautiful hair

After entering the growth phase again, the long-term health of hair follicles requires optimal microenvironment support. The Jingtai AI platform has designed the peptide molecule AquaKine for the entire hair growth cycle ™ (XTP-016)。

AquaKine™By acting on multiple key biomarkers during the hair growth cycle,Significantly improve the microenvironment of hair follicles, including promoting the generation of collagen and elastin, and enhancing the proliferation environment of hair follicle keratinocytes and stem cells⁴This effect directly enhances the health and nutritional supply of hair follicles, just like fertilizing roots, which can effectively reduce hair loss, consolidate existing hair, and provide strong support for the growth of new hair.

Completed human efficacy testing by professional testing institutions, as well as large-scale consumer grade real use testing of the brand formula for over six months⁵Jingtai Technology's innovative "Gemini" molecule demonstrates outstanding performance, fully verifying its product competitive advantages in terms of effective speed, significant efficacy, and high safety.

• Rapid onset of action:Research shows that participants are the fastest inAfter 14 days of useThe initial increase in hair follicle density during the growth phase can be observed⁶Fast onset of action.

• Significant effect:After 45 days of use,Over 90% of participants observed a visible increase in hair density to the naked eye⁷Average of participantsThe number of hair drops has decreased by 33% to 45%⁸Among them, the transformation of a level 4 hair loss subject who did not respond well to existing mainstream hair growth components is quite representative - within 20 days, their scalp has grown fine and soft hairs and gradually transformed into more robust hair growth⁹.

• 安全性高：More importantly, the formula demonstrates excellent safety performance. The product development has undergone strict screening and verification processes to ensure long-term safety and reliability. In a series of human efficacy tests¹⁰ In nearly a hundred real-life use cases, there have been no adverse reactions such as exacerbation of initial hair loss commonly seen in existing similar products¹¹Thanks to its good water solubility and excellent biocompatibility, the formula is gentle and non irritating, providing a comfortable and burden free experience.

Note: The data is sourced from third-party laboratories and testing institutions

Strength endorsement: Ten years of honed AI R&D engine

Remeanagen ™、 AquaKine ™ The birth of two efficient hair generating molecules is not accidental. Behind them is the AI molecule development platform ID4, which Jingtai Technology has invested billions of dollars and spent ten years carefully building and continuously optimizing iterations. This platform integrates a series of algorithm innovations, and its molecular discovery and rational design capabilities have been repeatedly validated in practical applications. ID4 platform has enabled Pfizer to rapidly develop anti COVID-19 oral medication Paxlovid^®To contribute to resolving the global pandemic crisis. Based on this platform, Jingtai Technology and Eli Lilly have signed high cooperation agreements for AI small molecule and AI biopharmaceutical research and development, helping Eli Lilly overcome extremely challenging drug targets. This platform also assisted innovative biotechnology company Sigma Biotech in developing the breakthrough diffuse gastric cancer candidate drug SIGX1094, and was nominated for the Nobel Prize in Biomedical Sciences - the Prix Galien USA. It is the powerful molecular prediction, design, and optimization capabilities of the ID4 platform that cleverly solve multiple challenges in the development of new hair growth components, turning seemingly "impossible" hair growth molecules into reality.

Business model: Empowering partners, co creating win-win outcomes

As the first consumer product project of Jingtai Technology, Remeanagen ™ With AquaKine ™ The successful development has strategic significance. The company has chosen to collaborate with a small Hong Kong listed technology company to promote the commercialization process of this innovative achievement. This cooperation not only confirms the strong empowering value of Jingtai Technology platform for small and medium-sized enterprises, which can help them achieve technological breakthroughs and market value leaps, but also ensures that Chinese consumers can experience the cutting-edge achievements of local source innovation in the first time.

Meanwhile, this business model has the potential to bring higher business returns to innovators. Compared to the single digit commercialization sharing ratio of cooperation with traditional large pharmaceutical companies, as a molecular IP holder, Jingtai Technology,This time, we will enjoy a sales share of up to double-digit percentageTo provide ample cash flow support for the research and development of more consumer health products in the future.

Opening a new era: AI molecules benefit people's livelihoods

With Remeanation ™ And AquaKine ™ Jingtai Technology has obtained key international authoritative certifications and is about to go public, officially opening a strategic new era of dual track drive for its AI platform:Not only does it focus on drug development for major diseases, but it also creates consumer level solutions to improve the quality of daily life for the general public.

This also gives Jingtai Technology a new mission:

Let AI flow into every new drug;

It also allows AI molecules to enter everyone's beautiful life.

Note: